Key Drivers
- High gross margins
- Negative net income
- Elevated leverage
AIAI Summary
BLCO has transitioned from a balance‑sheet restructuring story to an operational inflection—quarterly EBITDA improvement and recent positive quarter FCF indicate the company can convert multi‑segment revenue growth (notably MIEBO) into cash, making execution the primary re‑rating lever. Monitor sequential quarters of positive free cash flow, visible deleveraging or reduced interest burden, and a contained/legal resolution (any escalation, impairment, or recall would rapidly reverse gains).
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margins
- •Negative net income
- •Elevated leverage
BLCO combines strong gross margins and improving quarter-level EBITDA/FCF with persistent net losses, heavy operating spend, large intangibles and material leverage that together make its near-term operating resilience overshadowed by balance-sheet and earnings risks.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Approaching support
- •Elevated volatility
BLCO is biased lower—trading materially below its last month moving average after rolling over from a late‑February peak and making a fresh low on 2026‑03‑20 while approaching support in the $16.4–$16.8 area.
Several-percent range between the 2026‑02‑25 high and 2026‑03‑20 low indicating heightened short-term volatility
Sentiment & News
Key News Insights:
- •Product momentum
- •Caspian stake
- •Regulatory/legal risk
Bausch + Lomb shows product and R&D momentum with rising investor interest after solid revenue, but a new securities-fraud investigation introduces material legal risk.
Positive R&D and investor signals could buoy the stock short-term, but the investigation raises downside risk and likely increases volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings